A Feasibility study of MRI and PET Imaging to Assess Response toMK-3475 (Pembrolizumab) in Patients with Metastatic Melanoma
Sponsor: |
Merck & Co., Inc |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAO2558 |
Contact: |
Lauren Taiclet: 212-305-0455 / lt2646@cumc.columbia.edu |
The purpose of this study is to test two imaging techniques, one called whole body diffusion weighted magnetic resonance imaging (WB-DWI MRI), and another called F-18 3-deoxy-3-fluorothymidine PET (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with metastatic melanoma receiving MK-3475.
This study is closed
Investigator
Yvonne Saenger, MD
Do you have an untreated brain metastases or active central nervous system metastases? |
Yes |
No |